Holen Sie sich die Stockscreener-App
22.02
3.43%
0.73
Handel nachbörslich:
22.06
0.04
+0.18%
Schlusskurs vom Vortag:
$21.29
Offen:
$21.36
24-Stunden-Volumen:
206.90K
Relative Volume:
0.64
Marktkapitalisierung:
$1.50B
Einnahmen:
$350.00K
Nettoeinkommen (Verlust:
$-72.78M
KGV:
-20.39
EPS:
-1.08
Netto-Cashflow:
$-54.46M
1W Leistung:
-2.18%
1M Leistung:
+14.63%
6M Leistung:
+28.85%
1J Leistung:
+38.93%
1-Tages-Spanne:
$21.36
$22.29
1-Wochen-Bereich:
$20.55
$23.18
52-Wochen-Spanne:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
22.02 | 1.45B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Stock Analysis: Is Pulse Biosciences Inc exposed to currency risks2026 Short Interest & Risk Managed Trade Strategies - baoquankhu1.vn
(PLSE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System - MSN
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot - Sahm
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study - Yahoo Finance
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
What's Going With Pulse Biosciences Stock On Monday? - MSN
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones - MSN
Pulse Biosciences at Oppenheimer Conference: Promising AF Ablation Results By Investing.com - Investing.com Canada
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences shifts focus to cardiac catheter program By Investing.com - Investing.com South Africa
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter PlatformHas The Bull Case Changed? - simplywall.st
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results - Minichart
Pulse Biosciences Realigns Strategy Around nPulse AFib Platform - TipRanks
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program - Stock Titan
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - BioSpace
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program - marketscreener.com
Pulse Biosciences (PLSE) Prioritizes nPulse Cardiac Catheter Dev - GuruFocus
Pulse Biosciences shifts focus to cardiac catheter program - Investing.com
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Responsive Playbooks and the PLSE Inflection - Stock Traders Daily
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings - Sahm
Pulse Biosciences enrolls first patients in thyroid cancer study By Investing.com - Investing.com Canada
Pulse Biosciences Launches Thyroid Cancer Feasibility Study - TipRanks
Pulse Biosciences, Inc. Announces First Enrollments in Feasibilit - The National Law Review
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - The Joplin Globe
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors With NPulse Technology - 富途牛牛
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
Pulse Biosciences (PLSE) reports 74% benign thyroid nodule reduction in nsPFA study - Stock Titan
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
Why Pulse Biosciences Inc. stock could be next big winnerEarnings Recap Summary & Fast Entry and Exit Trade Plans - Naître et grandir
How strong is Pulse Biosciences Inc. (6L8) stock earnings growthDividend Hike & Low Volatility Stock Recommendations - Naître et grandir
Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Investing News Network
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum - Sahm
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - The Joplin Globe
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines - Investing.com
FinancialContentPulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - FinancialContent
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):